Cytokinetics Starts Trial For CK-586 In HFpEF
Cytokinetics, Inc. (CYTK), a biopharmaceutical company focused on muscle biology, on Monday announced the launch of the AMBER-HFpEF ...
Morningstar11d
Cytokinetics Announces 2025 Corporate Milestones and Vision 2030
SOUTH SAN FRANCISCO, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq: CYTK) today provided guidance for corporate milestones expected to occur in 2025 and outlined its ...
Cytokinetics announces start of AMBER-HFpEF, Phase 2 trial of CK-586
Cytokinetics (CYTK) announced that AMBER-HFpEF is open to enrollment. AMBER-HFpEF is a Phase 2 randomized, placebo-controlled, double-blind, ...
Nasdaq24d
Cytokinetics Grants Stock Options and Restricted Stock Units to New Employees as Inducement for Employment
Cytokinetics, Incorporated announced the granting of stock options and restricted stock units (RSUs) to nine new employees on December 31, 2024, as part of their employment inducement. The company ...
Finanznachrichten10d
Cytokinetics, Incorporated: Cytokinetics Announces 2025 Corporate Milestones and Vision 2030
PDUFA Target Action Date for Aficamten Set for September 26, 2025; Commercial Launch Preparations Underway for First Potential Approval Five-Year Aspirations Outline Corporate Strategies to Becoming ...